keyword
MENU ▼
Read by QxMD icon Read
search

Oligometastatic

keyword
https://www.readbyqxmd.com/read/27888148/a-pilot-study-of-a-multimodal-treatment-paradigm-to-accelerate-drug-evaluations-in-early-stage-metastatic-prostate-cancer
#1
Matthew J O'Shaughnessy, Sean M McBride, Hebert Alberto Vargas, Karim A Touijer, Michael J Morris, Daniel C Danila, Vincent P Laudone, Bernard H Bochner, Joel Sheinfeld, Erica S Dayan, Lawrence P Bellomo, Daniel D Sjoberg, Glenn Heller, Michael J Zelefsky, James A Eastham, Peter T Scardino, Howard I Scher
OBJECTIVE: To evaluate a multimodal strategy aimed at treating all sites of disease that provides a rapid readout of success or failure in men presenting with noncastrate metastatic prostate cancers that are incurable with single modality therapy. PATIENTS AND METHODS: Twenty selected men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis were treated using a multimodal approach that included androgen deprivation, radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease and/or the primary site...
November 22, 2016: Urology
https://www.readbyqxmd.com/read/27886588/the-expanding-role-of-stereotactic-body-radiation-therapy-in-oligometastatic-solid-tumors-what-do-we-know-and-where-are-we-going
#2
REVIEW
Julian C Hong, Joseph K Salama
The spectrum hypothesis posits that there are distinct clinical states of metastatic progression. Early data suggest that aggressive treatment of more biologically indolent metastatic disease, characterized by metastases limited in number and destination organ, may offer an opportunity to alter the disease course, potentially allowing for longer survival, delay of systemic therapy, or even cure. The development of stereotactic body radiation therapy (SBRT) has opened new avenues for the treatment of oligometastatic disease...
November 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27875625/clinical-and-genetic-determinants-of-ovarian-metastases-from-colorectal-cancer
#3
Karuna Ganesh, Ronak H Shah, Efsevia Vakiani, Garrett M Nash, Hugh P Skottowe, Rona Yaeger, Andrea Cercek, Anne Lincoln, Christina Tran, Neil H Segal, Diane L Reidy, Anna Varghese, Andrew S Epstein, Yukio Sonoda, Dennis Chi, Jose Guillem, Larissa Temple, Philip Paty, Jaclyn Hechtman, Jinru Shia, Martin Weiser, Julio Garcia Aguilar, Nancy Kemeny, Michael F Berger, Leonard Saltz, Zsofia K Stadler
BACKGROUND: Ovarian metastases from colorectal cancer (OM-CRC) often are unresponsive to chemotherapy and are associated with poor survival. To the authors' knowledge, the clinicopathologic and genomic predictors of OM-CRC are poorly characterized and optimal clinical management remains unclear. METHODS: Women with a histopathological diagnosis of OM-CRC who were treated at Memorial Sloan Kettering Cancer Center from 1999 to 2015 were identified. Next-generation somatic mutation profiling (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]) was performed on 38 OM-CRC cases, including 21 matched tumor pairs/trios...
November 22, 2016: Cancer
https://www.readbyqxmd.com/read/27872987/the-ir-evolution-in-oncology-tools-treatments-and-guidelines
#4
Thierry de Baere
Early focus of interventional oncologists was developing tools and imaging guidance, performing "procedures" acting as a skillful technician without knowledge of clinical patient outcomes, beyond post-treatment image findings. Interventional oncologists must deliver "treatments" and not "procedures", and focus on clinically relevant outcomes, provide clinical continuity of care, which means stand at multidisciplinary tumor boards, see patients in consultation before treatment and for follow-up. Interventional oncologists have fought for the same "market" with surgery in a head to head, bloody competition called red ocean strategy in marketing terms, resulting in many aborted trials...
November 21, 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27871270/might-radiation-therapy-in-addition-to-chemotherapy-improve-overall-survival-of-patients-with-non-oligometastatic-stage-iv-non-small-cell-lung-cancer-secondary-analysis-of-two-prospective-studies
#5
ShengFa Su, YinXiang Hu, WeiWei Ouyang, Zhu Ma, QingSong Li, HuiQin Li, Yu Wang, XiaoHu Wang, Tao Li, JianCheng Li, Ming Chen, You Lu, YuJu Bai, ZhiXu He, Bing Lu
BACKGROUND: The role of radiation therapy in addition to chemotherapy has not been well established in non-oligometastatic Stage IV non-small cell lung cancer (NSCLC). We aimed to investigate overall survival (OS) of non-oligometastatic Stage IV NSCLC treated with chemotherapy with concurrent radiation to the primary tumor. METHODS: Eligible patients were screened from two prospective studies. Oligometastatic and non-oligometastatic NSCLC were defined as having < 5 and ≥5 metastatic lesions, respectively...
November 21, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27870704/clinical-outcomes-for-stereotactic-ablative-radiotherapy-in-oligometastatic-and-oligoprogressive-gynecological-malignancies
#6
Shane Mesko, Kiri Sandler, Joshua Cohen, Gottfried Konecny, Michael Steinberg, Mitchell Kamrava
OBJECTIVES: We report single-institution clinical outcomes of women treated with stereotactic ablative radiotherapy (SABR) for oligometastatic or progressive gynecological malignancies. MATERIALS AND METHODS: From 2009 to 2015, 47 lesions from 28 patients were treated with SABR and retrospectively analyzed. All patients had oligometastatic (93%) or oligoprogressive (7%) disease. Primary cancer diagnoses were 15 ovarian, 8 endometrial, 2 cervical, 2 vaginal, and 1 uterine carcinosarcoma...
November 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27867337/oligometastatic-growing-teratoma-syndrome-a-case-for-an-aggressive-surgical-approach
#7
William S Gange, Robert H Blackwell, John Biemer, Güliz A Barkan, Maria M Picken, Marcus L Quek
Growing teratoma syndrome is an infrequent presentation of testicular cancer. We present a case of growing teratoma syndrome in a patient who initially presented with clinical stage I nonseminomatous testicular germ cell tumor, who subsequently developed large volume oligometastases to the retroperitoneum, thorax, and thigh. Despite two regimens of chemotherapy, his disease progressed. Complete surgical extirpation of all gross tumors confirmed mature teratoma. An aggressive surgical approach, including postchemotherapy resection of all known metastatic sites, can provide long-term disease-free survival...
October 2016: Current Urology
https://www.readbyqxmd.com/read/27866095/continuing-egfr-inhibition-beyond-progression-in-advanced-non-small-cell-lung-cancer
#8
REVIEW
Timothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a 'withdrawal tumour flare'...
November 17, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27863731/pulmonary-resection-for-synchronous-m1b-cstage-iv-non-small-cell-lung-cancer%C3%A2-patients
#9
Masafumi Yamaguchi, Makoto Edagawa, Yuzo Suzuki, Ryo Toyozawa, Fumihiko Hirai, Kaname Nosaki, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
BACKGROUND: We wanted to assess the efficacy of curative intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with synchronous M1b-distant metastases in a single organ or lesion. METHODS: Between 1995 and 2015, 23 consecutive synchronous M1b-cStage IV NSCLC patients who underwent any treatment for metastases and curative intent pulmonary resection were retrospectively analyzed. RESULTS: Sixteen patients were men and 7 were women, with a median age of 56 years (range: 41 to 76 years)...
November 15, 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27856064/radical-surgery-of-oligometastatic-pancreatic-cancer
#10
T Hackert, W Niesen, U Hinz, C Tjaden, O Strobel, A Ulrich, C W Michalski, M W Büchler
BACKGROUND: In metastatic disease (M1), chemotherapy (expected survival: 6-10 months) is considered the only treatment option. The aim of this study was to evaluate the outcome of curative M1 PDAC resections. METHODS: Prospective data of all patients undergoing primary tumour and metastasis resection for stage IV PDAC during a 12-year period was analysed regarding localisation (liver or distant interaortocaval lymph nodes; ILN), morbidity and survival. Patients were stratified with regard to syn- or metachronous metastases resection...
November 9, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27843031/influence-of-institutional-experience-and-technological-advances-on-outcome-of-stereotactic-body-radiation-therapy-for-oligometastatic-lung-disease
#11
Juliane Rieber, Nasrin Abbassi-Senger, Sonja Adebahr, Nicolaus Andratschke, Oliver Blanck, Marciana Duma, Michael J Eble, Iris Ernst, Michael Flentje, Sabine Gerum, Peter Hass, Christoph Henkenberens, Guido Hildebrandt, Detlef Imhoff, Henning Kahl, Nathalie Desirée Klass, Robert Krempien, Fabian Lohaus, Frank Lohr, Cordula Petersen, Elsge Schrade, Jan Streblow, Lorenz Uhlmann, Andrea Wittig, Florian Sterzing, Matthias Guckenberger
PURPOSE: Many technological and methodical advances have made stereotactic body radiotherapy (SBRT) more accurate and more efficient during the last years. This study aims to investigate whether experience in SBRT and technological innovations also translated into improved local control (LC) and overall survival (OS). METHODS AND MATERIALS: A database of 700 patients treated with SBRT for lung metastases in 20 German centers between 1997 and 2014 was used for analysis...
September 26, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27837451/percutaneous-image-guided-cryoablation-current-applications-and-results-in-the-oncologic-field
#12
Roberto Luigi Cazzato, Julien Garnon, Nitin Ramamurthy, Guillaume Koch, Georgia Tsoumakidou, Jean Caudrelier, Francesco Arrigoni, Luigi Zugaro, Antonio Barile, Carlo Masciocchi, Afshin Gangi
Percutaneous imaging-guided cryoablation (PICA) is a recently developed technique, which applies extreme hypothermia to destroy tumours under close imaging surveillance. It is minimally invasive, safe, repeatable, and does not interrupt or compromise other oncologic therapies. It presents several advantages over more established heat-based thermal ablation techniques (e.g. radiofrequency ablation; RFA) including intrinsic analgesic properties, superior monitoring capability on multi-modal imaging, ability to treat larger tumours, and preservation of tissue collagenous architecture...
December 2016: Medical Oncology
https://www.readbyqxmd.com/read/27796820/whole-body-diffusion-weighted-magnetic-resonance-imaging-wb-dw-mri-vs-choline-positron-emission-tomography-computed-tomography-choline-pet-ct-for-selecting-treatments-in-recurrent-prostate-cancer
#13
A J Conde-Moreno, G Herrando-Parreño, R Muelas-Soria, J Ferrer-Rebolleda, R Broseta-Torres, M P Cozar-Santiago, F García-Piñón, C Ferrer-Albiach
OBJECTIVE: To determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with biochemical relapse after primary treatment, and no metastases in bone scintigraphy, CT and/or pelvic MRI, or metastatic/oligometastatic prostate cancer (PCa). Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated...
October 31, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27789196/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for-patients-with-oligometastatic-non-small-cell-lung-cancer-without-progression-after-first-line-systemic-therapy-a-multicentre-randomised-controlled-phase-2-study
#14
Daniel R Gomez, George R Blumenschein, J Jack Lee, Mike Hernandez, Rong Ye, D Ross Camidge, Robert C Doebele, Ferdinandos Skoulidis, Laurie E Gaspar, Don L Gibbons, Jose A Karam, Brian D Kavanagh, Chad Tang, Ritsuko Komaki, Alexander V Louie, David A Palma, Anne S Tsao, Boris Sepesi, William N William, Jianjun Zhang, Qiuling Shi, Xin Shelley Wang, Stephen G Swisher, John V Heymach
BACKGROUND: Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative therapy for patients with oligometastatic NSCLC is unknown. We aimed to assess the effect of local consolidative therapy on progression-free survival. METHODS: In this multicentre, randomised, controlled, phase 2 study, eligible patients from three hospitals had histological confirmation of stage IV NSCLC, three or fewer metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group performance status score of 2 or less, had received standard first-line systemic therapy, and had no disease progression before randomisation...
October 24, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27787754/oligometastatic-prostate-cancer
#15
REVIEW
Daniel J Stevens, Prasanna Sooriakumaran
The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatment to their primary tumour alongside 'metastasis-directed therapy' to the metastatic deposits. However, this regimen should be reserved to high-volume centres with quality assurance programmes and excellent outcomes...
December 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/27785766/impact-of-68-ga-psma-pet-ct-on-salvage-radiotherapy-planning-in-patients-with-prostate-cancer-and-persisting-psa-values-or-biochemical-relapse-after-prostatectomy
#16
Christina Bluemel, Fraenze Linke, Ken Herrmann, Iva Simunovic, Matthias Eiber, Christian Kestler, Andreas K Buck, Andreas Schirbel, Thorsten A Bley, Hans-Juergen Wester, Daniel Vergho, Axel Becker
BACKGROUND: Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced (68)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning. Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent (68)Ga-PSMA PET/CT...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27780780/role-of-local-ablative-therapy-in-patients-with-oligometastatic-and-oligoprogressive-non-small-cell-lung-cancer
#17
REVIEW
Chul Kim, Chuong D Hoang, Aparna H Kesarwala, David S Schrump, Udayan Guha, Arun Rajan
Due to an improved understanding of lung cancer biology and improvement in systemic treatment, an "oligometastatic" state where metastatic disease is present at a limited number of anatomic sites is being increasingly recognized. An "oligoprogressive" state, a similar but distinct entity, refers to disease progression at a limited number of anatomic sites with continued response or stable disease at other sites of disease. Such an oligoprogressive state is best described in patients with non-small-cell lung cancer (NSCLC) treated with molecular targeted therapy...
October 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27777776/high-dose-interleukin2-a-10-year-single-site-experience-in-the-treatment-of-metastatic-renal-cell-carcinoma-careful-selection-of-patients-gives-an-excellent-outcome
#18
S Chow, V Galvis, M Pillai, R Leach, E Keene, A Spencer-Shaw, A Shablak, J Shanks, T Liptrot, F Thistlethwaite, R E Hawkins
BACKGROUND: VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy treatment capable of durable remission in some patients but its unselected use has been difficult due to its modest response rate and considerable adverse effects. Using set pathology criteria as a selection tool in clinical practice, we have been able to show improved outcomes in our previous report...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27755813/clinical-outcome-of-node-negative-oligometastatic-non-small-cell-lung-cancer
#19
Kiyohiro Sakai, Masayuki Takeda, Hidetoshi Hayashi, Kaoru Tanaka, Takeshi Okuda, Amami Kato, Yasumasa Nishimura, Tetsuya Mitsudomi, Atsuko Koyama, Kazuhiko Nakagawa
INTRODUCTION: The concept of "oligometastasis" has emerged as a basis on which to identify patients with stage IV non-small cell lung cancer (NSCLC) who might be most amenable to curative treatment. Limited data have been available regarding the survival of patients with node-negative oligometastatic NSCLC. PATIENTS AND METHODS: Consecutive patients with advanced NSCLC who attended Kindai University Hospital between January 2007 and January 2016 were recruited to this retrospective study...
September 12, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27745995/implementation-of-a-volumetric-modulated-arc-therapy-treatment-planning-solution-for-kidney-and-adrenal-stereotactic-body-radiation-therapy
#20
Marcus Sonier, William Chu, Nafisha Lalani, Darby Erler, Patrick Cheung, Renee Korol
To develop a volumetric modulated arc therapy (VMAT) treatment planning solution in the treatment of primary renal cell carcinoma and oligometastatic adrenal lesions with stereotactic body radiation therapy. Single-arc VMAT plans (n = 5) were compared with clinically delivered step-and-shoot intensity-modulated radiotherapy (IMRT) with planning target volume coverage normalized between techniques. Target volume conformity, organ-at-risk (OAR) dose, treatment time, and monitor units were compared. A VMAT planning solution, created from a combination of arc settings and optimization constraints, auto-generated treatment plans in a single optimization...
October 13, 2016: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
keyword
keyword
65559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"